- /
- Supported exchanges
- / US
- / ALDX.NASDAQ
Aldeyra The (ALDX NASDAQ) stock market data APIs
Aldeyra The Financial Data Overview
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aldeyra The (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Aldeyra The data using free add-ons & libraries
Get Aldeyra The Fundamental Data
Aldeyra The Fundamental data includes:
- Net Revenue:
- EBITDA: -19 844 448
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-11
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aldeyra The News
New
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Ultragenyx Pharmaceutical RARE has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. The company received the voucher after the FDA a...
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Alto Neuroscience ANRO is a clinical-stage biopharmaceutical company focused on developing medicines for mental health disorders, including depression, bipolar depression and schizophrenia-related cog...
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Pharmaceuticals SNDX shares fell 15.7% on Tuesday after the company reported that its mid-stage study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. T...
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Prime Medicine PRME shares have gained approximately 26% over the past month against the industry's 2.8% decline, supported by encouraging clinical and regulatory progress across its gene-editing pipe...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.